Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.49 |
| ▸ | PTPN22 | Q9Y2R2 | 4/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA9 | Q16790 | 4/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18494972 | 0.93 | CYP3A4 (0.45) | PTPN1PTPN22CA12CA1CA2 | |
| SCHEMBL23318034 | 0.92 | SCN9A (0.48) | PTPN1PTPN22CA12CA1CA2 | |
| SCHEMBL17839814 | 0.90 | PTPN1 (0.45) | PTPN1PTPN22CA12CA1CA2 | |
| SCHEMBL29453445 | 0.90 | PTPN1 (0.45) | PTPN1PTPN22CA12CA1CA2 | |
| SCHEMBL17839574 | 0.90 | PTPN1 (0.45) | PTPN1PTPN22CA12CA1CA2 | |
| SCHEMBL29453449 | 0.90 | PTPN1 (0.45) | PTPN1PTPN22CA12CA1CA2 | |
| SCHEMBL19975481 | 0.90 | CA12 (0.52) | CA12CA1CA2CA9DRD2 | |
| SCHEMBL24172945 | 0.89 | PTPN1 (0.46) | PTPN1PTPN22CA12CA1CA2 | |
| SCHEMBL2892290 | 0.87 | PTPN1 (0.61) | PTPN1PTPN22 | |
| SCHEMBL20919631 | 0.85 | CA12 (0.50) | PTPN1PTPN22CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | MDM2, STUB1, UBE3C | PTPN1 2052/4885PTPN22 2617/4885CA12 4284/4885 |
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | MDM2, STUB1, UBE3C | PTPN1 2052/4885PTPN22 2617/4885CA12 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.